ArticleJournal of clinical microbiology2004
Rapid identification of Nocardia farcinica clinical isolates by a PCR assay targeting a 314-base-pair species-specific DNA fragment.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Case report: Pathology, antimicrobial resistance, and molecular characterization of bovine abortion cases caused byFrontiers in veterinary science · 2024Article
- Analytical and clinical validation of multiplex droplet digital PCR assay for detecting pathogenic fungal infection in lungs.Mycology · 2024Article
- Updated Review onClinical microbiology reviews · 2022Review
- Nocardia farcinica pituitary abscess in an immunocompetent patient: illustrative case.Journal of neurosurgery. Case lessons · 2022Article
- CRISPR/Cas12a-Based Diagnostic Platform Accurately DetectsFrontiers in cellular and infection microbiology · 2022Article
- Current diagnostic tools and management modalities of Nocardia keratitis.Journal of ophthalmic inflammation and infection · 2020Review
- Invasive Nocardiosis: Disease Presentation, Diagnosis and Treatment - Old Questions, New Answers?Infection and drug resistance · 2020Review
- Molecular identification ofNew microbes and new infections · 2017Article
- Comments on: Phenotypic and Molecular Identification of Nocardia in Brain Abscess.Advanced biomedical research · 2017Article
- Pulmonary nocardiosis associated with cerebral abscess successfully treated by co-trimoxazole: a case report.Folia microbiologica · 2014Article
- Diagnosis of tuberculosis by trained African giant pouched rats and confounding impact of pathogens and microflora of the respiratory tract.Journal of clinical microbiology · 2012Article
- Nocardia farcinica lung infection in a patient with cystic fibrosis: a case report.Journal of medical case reports · 2010Article
- Identification of pathogenic Nocardia species by reverse line blot hybridization targeting the 16S rRNA and 16S-23S rRNA gene spacer regions.Journal of clinical microbiology · 2010Article
- Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy.Clinical microbiology reviews · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nocardia farcinica is the most clinically significant species within the Nocardia asteroides complex. Differentiation of N. farcinica from other members of N. asteroides complex is important because this species characteristically demonstrates resistance to several extended-spectrum antimicrobial agents. Traditional phenotypic characterization of this species is time- and labor-intensive and often leads to misidentification in the clinical microbiology laboratory. We previously observed a 409-bp product for all strains of N. farcinica by using randomly amplified polymorphic DNA analysis with the primer DKU49. In this investigation, the 409-bp fragment was sequenced and then used to design a specific primer pair, Nf1 (16-mer) and Nf2 (16-mer), complementary to the 409-bp fragment. PCR amplification of genomic DNA from 28 N. farcinica isolates with Nf1 and Nf2 generated a single intense 314-bp fragment. The specificity of the assay with these primers was verified, since there were no PCR amplification products observed from heterologous nocardial species (n = 59) or other related bacterial genera (n = 41). Restriction enzyme digestion using CfoI and direct sequencing of the 314-bp fragment further confirmed the specificity of the assay for N. farcinica. This highly sensitive and specific PCR assay provides a rapid (within 1 day of obtaining DNA) method for identification of this medically important emerging pathogen. Rapid diagnosis of N. farcinica infection may allow for earlier initiation of effective therapy, thus improving patient outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.